Bausch Health Companies (TSE:BHC) has released an update.
Bausch Health Companies Inc. and its subsidiary Salix Pharmaceuticals have initiated a patent infringement lawsuit against Norwich Pharmaceuticals for seeking FDA approval to market a generic version of XIFAXAN®, a drug for irritable bowel syndrome. This follows a prior court ruling that protected Bausch Health’s XIFAXAN® patent until October 2029. The company emphasizes its dedication to defending its intellectual property and ensuring patient safety.
For further insights into TSE:BHC stock, check out TipRanks’ Stock Analysis page.
